Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.”In the company’s words, NCT05381181 on ClinicalTrials.gov
- Tested for
- Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
- Main trialPhase 1
- “The purpose of this study is to evaluate the safety and efficacy of Next-generation CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.”In the company’s words, NCT05381181 on ClinicalTrials.gov
Other drugs for Acute Lymphoblastic Leukemia
- TisagenlecleucelNovartis · Phase 3
- VenetoclaxAbbVie · Phase 3
- RemimazolamAcacia Pharma Ltd · Phase 2/3
- BlinatumomabAmgen · Phase 3
- OlverembatinibAscentage Pharma Group Inc. · Phase 3
- Orca-TOrca Biosystems, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Unknown | 30 May 2024 | Safety and Efficacy Evaluation of Next-generation CD19-UCART |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026